Laninamivir

Drug Profile

Laninamivir

Alternative Names: CS-8958; Inavir; LANI; Laninamivir octanoate; Laninamivir octanoate hydrate; R-118958

Latest Information Update: 03 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Daiichi Sankyo Company
  • Developer Aviragen Therapeutics; Daiichi Sankyo Company
  • Class Antivirals; Guanidines; Small molecules
  • Mechanism of Action Neuraminidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 30 Jun 2017 Daiichi Sankyo completes a phase III trial for Influenza virus infections (In neonates, In infants, In children) in Japan (Inhalation) (JapicCTI-163398)
  • 30 Jun 2017 Daiichi Sankyo completes a phase III trial for Influenza virus infections (In children, In adolescents, In adults, In the elderly) in Japan (Inhalation) (JapicCTI-163397)
  • 02 Feb 2017 Daiichi Sankyo initiates phase III trial for Influenza infections (nebuliser formulation) in Japan before February 2017 (Daiichi Sankyo pipeline, February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top